Blindness — Epidemiology & NPCB

Blindness is a major public-health problem in India that is largely avoidable (preventable + curable). This topic is examiner-favourite for its precise WHO visual-acuity cut-offs, the leading-cause ranking (cataract on top), cataract surgical rate (CSR) targets, and the SAFE strategy for trachoma. Get the numbers exact — most questions are pure recall of cut-offs and percentages.

Definitions & WHO classification

The WHO classification of visual impairment is based on presenting visual acuity in the better eye. The two most heavily tested numbers are blindness (<3/60) and the upper threshold of normal/near-normal (≥6/18).

Category	Presenting VA (better eye)	Snellen equivalent
Normal / near-normal vision	≥6/18	6/6 to 6/18
Low vision (visual impairment)	<6/18 to 3/60	moderate + severe
— Moderate visual impairment	<6/18 to 6/60	—
— Severe visual impairment	<6/60 to 3/60	—
Blindness (WHO)	<3/60 (or field <10°)	counting fingers <3 m
Economic blindness	<3/60 (cannot count fingers in daylight)	WHO definition
Social blindness	<1/60 to PL+	—

High-yield: WHO defines blindness as visual acuity <3/60 in the better eye with best correction, OR a corresponding field loss to <10° around central fixation. Memorise 3/60 as the single most-asked figure.

High-yield: Low vision = VA <6/18 down to 3/60 in the better eye. The cut-off 6/18 separates normal from low vision; 3/60 separates low vision from blindness.

National (India / NPCB) definition of blindness differs from WHO and is itself examinable: VA <6/60 (or <20/200) in the better eye with best correction, OR field <20°. India adopted this broader cut-off (6/60 instead of 3/60) so that more people qualify for services.

High-yield: WHO blindness = <3/60; Indian (NPCB) blindness = <6/60. This contrast is a classic single-best-answer trap.

ICD-11 / new WHO terminology has moved to "distance visual impairment" (mild, moderate, severe) and "blindness", plus "near visual impairment". For NEET PG, the older categorical table above is still the safest to reproduce.

Magnitude of the problem

• Global blind population: ~43 million (recent Global Burden estimates); ~295 million with moderate-to-severe visual impairment.
• India contributes the largest share of the world's blind.
• National Blindness & Visual Impairment Survey (2015–19): prevalence of blindness in the ≥50 yr age group ~1.99% (down from earlier ~8% surveys); all-age prevalence ~0.36%. India's National Health Policy 2017 target was to reduce blindness prevalence to 0.3%.
• Older NPCB figure frequently quoted in texts: blindness prevalence ~1.1% (NSSO/older surveys) — know that the trend is declining, driven mainly by cataract surgery.

High-yield: Most blindness in India (and worldwide) is avoidable — roughly 80% preventable or curable. This single fact underpins the entire NPCB rationale.

Leading causes of blindness in India

The cause ranking is one of the most repeated MCQs. Cataract is number one by a wide margin.

Rank	Cause	Approx. share
1	Cataract	~66–70% (about two-thirds)
2	Refractive error (uncorrected)	~19–20%
3	Glaucoma	~5–6%
4	Posterior segment / retina (incl. diabetic retinopathy, ARMD)	~5%
5	Corneal blindness (incl. trachoma, keratitis, vit-A)	~1–4%
6	Surgical complications / others	remainder

High-yield: Cataract ≈ 66% (two-thirds) of blindness in India — the leading cause. Refractive error is the leading cause of visual impairment/low vision and the commonest cause overall when impairment is included.

Global leading causes: cataract is the leading cause of blindness; uncorrected refractive error is the leading cause of moderate-to-severe visual impairment.

Childhood blindness in India: leading avoidable cause historically vitamin A deficiency (corneal); with control programmes, retinopathy of prematurity (ROP) and congenital causes (cataract, glaucoma) are rising. Whole-population corneal blindness is dominated by infections, trauma, and vitamin A deficiency.

NPCB → NPCBVI (the programme)

• Launched 1976 as the National Programme for Control of Blindness (NPCB) — India's first 100% centrally sponsored health programme.
• Goal at launch: reduce blindness prevalence from 1.4% to 0.3%.
• Renamed in 2017 to National Programme for Control of Blindness & Visual Impairment (NPCBVI) to formally include visual impairment.
• Built on the global VISION 2020: The Right to Sight initiative (WHO + IAPB), launched 1999, targeting elimination of avoidable blindness by 2020.

High-yield: NPCB was launched in 1976 and was the first fully (100%) centrally funded national health programme in India. Renamed NPCBVI in 2017.

Administrative structure (stepwise flow):

Central (NPCB cell, DGHS) → State Health Society / State Programme Officer → District Blindness Control Society (DBCS) → PHC / Vision Centre & Mobile units.

The District Blindness Control Society (DBCS) is the key operational unit at district level, registered as a society to receive and disburse funds and coordinate NGOs and private surgeons.

VISION 2020 priority diseases (mnemonic: "CRRTCD")

Cataract, Refractive error, Retinopathy (childhood / diabetic), Trachoma, Corneal blindness/onchocerciasis (globally), Diabetic retinopathy & glaucoma. For India the priority list is: cataract, refractive error & low vision, childhood blindness, corneal blindness, glaucoma, diabetic retinopathy.

Cataract Surgical Rate (CSR) & coverage

CSR is the principal output indicator of cataract control.

• Cataract Surgical Rate (CSR): number of cataract surgeries performed per 1 million (10 lakh) population per year.
• India's CSR has risen from ~1500 to >6000 per million; the target is >5000–6000 per million to clear the backlog.
• Cataract Surgical Coverage (CSC): proportion of people with bilateral cataract blindness who have received surgery in one or both eyes — a coverage/outcome measure, complements CSR.

High-yield: CSR = cataract operations per 1 million population per year. Don't confuse with CSC (coverage, expressed as %). The shift in surgical technique has been ICCE → ECCE → phacoemulsification with IOL (intra-ocular lens) implantation, and the programme now emphasises good visual outcome, not just numbers operated.

Quality benchmark: WHO recommends post-operative good outcome (VA ≥6/18) in ≥80% of operated eyes with available correction.

SAFE strategy for trachoma

Trachoma (chlamydial keratoconjunctivitis, Chlamydia trachomatis serotypes A, B, Ba, C) is the leading infectious cause of blindness worldwide and the target of the WHO GET 2020 (Global Elimination of Trachoma) alliance. The control package is the SAFE strategy.

Letter	Component	Purpose
S	Surgery	for trichiasis/entropion (bilamellar tarsal rotation) to prevent corneal scarring
A	Antibiotics	mass drug administration — single-dose azithromycin (oral) or 1% tetracycline eye ointment
F	Facial cleanliness	reduces transmission via eye-seeking flies and fomites
E	Environmental improvement	safe water, sanitation, fly control

High-yield: SAFE = Surgery, Antibiotics, Facial cleanliness, Environmental improvement. Antibiotic of choice for mass treatment is single-dose oral azithromycin (20 mg/kg); alternative is 1% tetracycline ointment BD ×6 weeks.

India was declared FREE of active (infective) trachoma as a public-health problem by the WHO in 2024–25 (officially eliminated as a public-health problem), though residual trichiasis surveillance continues. Trachoma transmission classically follows the "F" word vectors — Fingers, Fomites, Flies, Fluid (ocular discharge).

WHO simplified grading of trachoma (FISTO):

1. TF — Trachomatous inflammation, Follicular (≥5 follicles on upper tarsal conjunctiva)
2. TI — Trachomatous inflammation, Intense
3. TS — Trachomatous conjunctival Scarring
4. TT — Trachomatous Trichiasis (≥1 lash touching globe) → needs Surgery
5. CO — Corneal Opacity → end-stage blinding lesion

High-yield: WHO grading mnemonic "FISTO" — Follicular, Intense, Scarring, Trichiasis, Opacity (TF, TI, TS, TT, CO). Herbert's pits (limbal follicle scars) and Arlt's line (tarsal scar) are pathognomonic eponyms.

Diagnosis & screening approach

• Visual acuity by Snellen chart at 6 m is the screening test of choice; illiterate E-chart / Landolt C for non-literate populations.
• Community surveys use rapid assessment of avoidable blindness (RAAB) methodology, sampling the ≥50 yr group where most blindness concentrates.
• Refraction for refractive error; slit-lamp for cataract/cornea; tonometry + optic disc + fields for glaucoma; fundus/dilated retinal exam / fundus photography for diabetic retinopathy and ROP.
• School eye screening (under NPCBVI) targets uncorrected refractive error — free spectacles to schoolchildren.

Stepwise community approach to a cataract-blind person:

1. Detection at Vision Centre / camp →
2. VA + refraction →
3. Diagnosis (mature/immature cataract) →
4. Referral to base hospital for phaco/ECCE + IOL →
5. Post-op follow-up & spectacle correction →
6. Record visual outcome (≥6/18 = good).

Management / drug & intervention of choice

• Cataract: definitive cure is surgery — phacoemulsification with foldable IOL (microsurgery, day-care). No medical cure.
• Refractive error: spectacles / contact lenses / refractive surgery — and uncorrected refractive error is the cheapest, most cost-effective blindness to address.
• Trachoma (individual): oral azithromycin single dose; mass = SAFE.
• Vitamin A deficiency (xerophthalmia): vitamin A prophylaxis — under-5 megadose schedule (1 lakh IU at 9 months, then 2 lakh IU every 6 months up to 5 years) prevents corneal blindness (nutritional blindness programme).
• Glaucoma: topical prostaglandin analogues / beta-blockers, laser, surgery — early detection is key as damage is irreversible.
• Diabetic retinopathy: glycaemic/BP control + laser photocoagulation / anti-VEGF; screen all diabetics.

Complications & consequences

• Irreversible blindness if cataract left to hypermature (phacolytic/phacomorphic glaucoma).
• Trachoma: trichiasis → corneal scarring → corneal opacity & blindness; superadded bacterial infection.
• Economic/social burden: loss of productivity, dependency; disproportionately affects the poor, elderly, and females (gender gap — women have higher blindness prevalence and lower surgical coverage).
• Surgical complications: endophthalmitis, posterior capsular opacification, surgically-induced astigmatism — hence emphasis on quality, not just CSR.

Key differentials & distinctions to keep straight

Confused pair	Correct distinction
WHO vs Indian blindness	<3/60 (WHO) vs <6/60 (NPCB)
Low vision vs blindness	<6/18–3/60 vs <3/60
Leading cause of blindness vs visual impairment	Cataract vs refractive error
CSR vs CSC	surgeries per million/yr vs % coverage of cataract-blind
Economic vs social blindness	<3/60 (can't count fingers daylight) vs <1/60
Avoidable vs unavoidable	preventable + curable (~80%) vs genetic/degenerative

Recently asked / exam angle

• "WHO definition of blindness?" → VA <3/60 in better eye / field <10°.
• "Commonest cause of blindness in India?" → Cataract (~66%).
• "Commonest cause of treatable/avoidable visual impairment / overall?" → Refractive error.
• "CSR is expressed per…?" → per million population per year.
• "SAFE strategy is for?" → Trachoma; expand all four letters; drug = azithromycin.
• "NPCB launched in?" → 1976, first 100% centrally sponsored programme; renamed NPCBVI 2017.
• "VISION 2020 tagline?" → The Right to Sight.
• "Indian (national) definition of blindness?" → <6/60.
• Image-based: Herbert's pits / Arlt's line → trachoma; trichiasis → SAFE "S".
• "Cut-off for low vision lower limit?" → 3/60, upper 6/18.

Rapid revision

1. WHO blindness = VA <3/60 in better eye (or field <10°); Indian/NPCB blindness = <6/60.
2. Low vision = <6/18 to 3/60 in the better eye.
3. Cataract is the leading cause of blindness in India (~66%, two-thirds).
4. Uncorrected refractive error is the leading cause of visual impairment globally and overall.
5. ~80% of blindness is avoidable (preventable + curable).
6. NPCB launched 1976 — India's first 100% centrally sponsored health programme; renamed NPCBVI in 2017.
7. VISION 2020: The Right to Sight (WHO + IAPB, 1999) is the global backbone.
8. CSR = cataract surgeries per 1 million population per year; India target >5000–6000.
9. SAFE = Surgery, Antibiotics (azithromycin), Facial cleanliness, Environmental improvement — for trachoma.
10. Trachoma grading FISTO (TF, TI, TS, TT, CO); eponyms Herbert's pits & Arlt's line.
11. District Blindness Control Society (DBCS) is the key district-level operational unit.
12. Cataract cure is surgical (phaco + IOL) — no medical treatment; aim ≥80% post-op VA ≥6/18.